Article ; Online: Prediction of musculoskeletal pain after the first intravenous zoledronic acid injection in patients with primary osteoporosis: development and evaluation of a new nomogram.
2023 Volume 24, Issue 1, Page(s) 841
Abstract: Objective: To construct a new prediction nomogram to predict the risk of musculoskeletal pain in patients with primary osteoporosis who receive zoledronic acid intravenously for the first time.: Method: Clinical data of 368 patients with primary ... ...
Abstract | Objective: To construct a new prediction nomogram to predict the risk of musculoskeletal pain in patients with primary osteoporosis who receive zoledronic acid intravenously for the first time. Method: Clinical data of 368 patients with primary osteoporosis who received the first intravenous injection of zoledronic acid in our hospital from December 2019 to December 2022 were studied. Patients were divided into a musculoskeletal pain group (n = 258) and a non-musculoskeletal pain group (n = 110) based on the presence or absence of musculoskeletal pain 3 days after injection. Statistically significant predictors were screened by logistic regression analysis and the minimum absolute contraction and selection operator (LASSO) to construct a nomogram. The nomogram was evaluated by the receiver operating characteristic (ROC) curve, the calibration curve, the C-index, and the decision curve analysis (DCA) and verified in a validation cohort. Results: The independent predictors of the nomogram were age, serum 25-hydroxyvitamin D, NSAIDs, prior Vitamin D intake, and BMI. The area under the ROC curve (AUC) was 0.980 (95% CI, 0.915-0.987), showing excellent predictive performance. The nomogram c index was 0.980, and the nomogram c index for internal verification remained high at 0.979. Moreover, calibration curves show that the nomogram has good consistency. Finally, the DCA showed that the net benefit of the nomogram was 0.20-0.49. Conclusion: Musculoskeletal pain is a common symptom of APR in OP patients treated with intravenous zoledronic acid. Risk factors for musculoskeletal pain after zoledronic acid injection in OP patients were: non-use of NSAIDs, youth (<80 years old), serum 25 (OH) D<30ng /mL, no prior intake of vitamin D, BMI<24 kg /m |
---|---|
MeSH term(s) | Adolescent ; Humans ; Aged, 80 and over ; Musculoskeletal Pain/chemically induced ; Musculoskeletal Pain/diagnosis ; Musculoskeletal Pain/drug therapy ; Nomograms ; Zoledronic Acid/adverse effects ; Vitamin D ; Anti-Inflammatory Agents, Non-Steroidal ; Osteoporosis/drug therapy |
Chemical Substances | Zoledronic Acid (6XC1PAD3KF) ; Vitamin D (1406-16-2) ; Anti-Inflammatory Agents, Non-Steroidal |
Language | English |
Publishing date | 2023-10-25 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 2041355-5 |
ISSN | 1471-2474 ; 1471-2474 |
ISSN (online) | 1471-2474 |
ISSN | 1471-2474 |
DOI | 10.1186/s12891-023-06965-y |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.